Network-Driven Analysis Methods and their Application to Drug Discovery

Network-Driven Analysis Methods and their Application to Drug Discovery

Daniel Ziemek (Pfizer Inc., USA) and Christoph Brockel (Pfizer Inc., USA)
DOI: 10.4018/978-1-60960-491-2.ch013
OnDemand PDF Download:
List Price: $37.50


Drug discovery and development face tremendous challenges to find promising intervention points for important diseases. Any therapeutic agent targeting such an intervention point must prove its efficacy and safety in patients. Success rates measured from first studies in human to registration average around 10% only. Over the last decade, massive knowledge on biological systems has been accumulated and genome-scale primary data are produced at an ever increasing rate. In parallel, methods to use that knowledge have matured. This chapter will present some of the problems facing the pharmaceutical industry and elaborate on the current state of network-driven analysis methods. It will focus especially on semi-quantitative methods that are applicable to large-scale data analysis and point out their potential use in many relevant drug discovery challenges.
Chapter Preview


Drug discovery and development continues to be a high-risk endeavor. Success rates for small molecule therapeutics average to around 10% from entry into Phase 1 (‘First in Human’) to successful registration across therapeutic indications and companies (Kola & Landis, 2004).

While historically much of the attrition was based on safety issues identified in Phase 1, more recent data indicate that the average success rate in Phase 1 has climbed to 60% and the success rates in Phase 2 and Phase 3 have reached 30-40% and 60%, respectively. Failure of a compound in a late stage of development is particularly undesirable, since it has then already incurred most of its total cost. With the total cost of drug discovery and development estimated to approach, and frequently exceed, $1B per registration, reduction in late stage attrition will be critical to affordable therapeutics.

In the pharmaceutical industry, the path to a therapy starts in many cases with the selection of a target, the intervention point that promises to cure or at least treat the disease of interest. Finding the right target is both crucial and non-trivial and there are several different approaches in use. The association of a clinical phenotype with a genetic mutation is very promising, since observations are made directly in human. Unfortunately, even in the case of monogenic diseases where the cause for the clinical phenotype can be linked to a single mutation, this information does not always lead directly to selection of a target. Reasons can be that the activity of the mutated protein cannot be modulated by a small molecule compound or that the mutation doesn’t result in any direct change of a protein at all. Good examples for this problem are the known MODY (‘Maturity Onset Diabetes of the Young’) gene mutations causing early-onset diabetes by rendering the corresponding proteins non-functional. No compounds have been found to counteract this loss-of-function directly. The ‘phenotype-mutation-target’ approach fails completely for multigenic, complex diseases. Methodologies are needed to mechanistically connect the genetic layer to the clinical phenotype to then enable selection of optimal intervention points.

Once the target is identified, the search for compounds or biologicals that demonstrate selective activity against the target, in in-vitro assays and in-vivo models of the disease begins. These programs are typically lengthy and produce optimized molecules that still fail about half of the time in safety studies in human - often caused by off-target effects. The ones that pass that hurdle then frequently fail to demonstrate efficacy.

The development of technologies that enable the collection of comprehensive ‘genome wide’, data in biological systems – frequently referred to as ‘OMICs’ technologies has created the promise to understand human biology and disease on a molecular and mechanistic level.

Dramatic improvements in speed, throughput and cost to sequence DNA and RNA are adding to this promise and introduce the possibility to understand genetic drivers for complex diseases and possibly differences in susceptibility to treatment in different sub-populations. Personalized medicine, the matching of the right treatment for the individual patient seems within reach.

While system wide generation of experimental data in disease models and to some degree in human is feasible today, the interpretation of these data for specific, testable hypotheses is still a significant bottleneck.

As illustrated in Figure 1, the approach to understand disease and drug action involves several stages from experiment to data generation and analysis. Integrating experimental results – possibly recorded at different levels (transcript, protein abundance, protein modification, etc) - with existing biological knowledge is a key step towards interpretation and hypothesis generation. Pathway or network analysis promises to provide the missing link between the lists of statistically significant findings from experiments and the understanding of the underlying biological mechanisms.

Figure 1.

Mechanistic understanding of disease and drug action involves several stages: (a) multiple model systems need to be perturbed and interrogated; (b) data from these experiments are generated on multiple molecular levels; (c) primary statistical analysis of these data leads to lists of observed molecular changes that need to be integrated with existing knowledge and finally (d) interpretation of the results to create hypotheses for target selection and compound progression.

Key Terms in this Chapter

Target: Key molecular entity that is causally involved in the pathogenesis or manifestation of a disease and can be modulated by therapeutic agents (e.g., small molecule drugs or antibodies).

Biomarker: Simple or complex measurable indicator of disease state, therapeutic efficacy or adverse effect. In the context of this article, the term is specifically used to describe molecular readouts with mechanistic relationship to the intervention.

Gene Set: List of biological objects associated with a particular context, e.g., result of an experiment or biological process. The term ‘gene’ is used loosely to include references to genes, transcripts and proteins.

Biological Network: A set of biological objects (molecules, concepts) and relationships. In this article, network is used synonymously with ‘graph’.

Pathway: Defined set of biological molecules and interactions that are associated with a biological concept (e.g. apoptosis, EGF signaling, etc.). In this context, a pathway is typically associated with a defined graphical layout.

Transcriptomic Data: Results of transcript abundance measurements (typically large scale), used interchangeably with ‘expression’ or ‘gene expression’ data.

Complete Chapter List

Search this Book: